HC Wainwright Rates Phathom Pharmaceuticals (PHAT) buy

HC Wainwright maintains its buy rating for PHAT, setting a $26 price target, a 149.28% upside from the current price.

By EarningsIQ Research Desk · Published Jun 17, 2026, 7:01 AM EDT · Updated Jun 18, 2026, 2:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Phathom Pharmaceuticals, Inc. ($PHAT) "buy" with a $26 price target on June 17, 2026.

Since the rating, $PHAT is down 3.5% after 1 week, down 0.6% after 1 month and down 37.1% to date (from the $11 close on Jun 17, 2026).

PHAT Phathom Pharmaceuticals, Inc.

$6.92 -55.95% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating for PHAT on June 17, 2026, with a price target of $26.
HC Wainwright's $26 price target implies 149.28% upside from Phathom Pharmaceuticals, Inc.'s ($PHAT) current $10.43 share price.
Shares of PHAT traded at $10.43, with institutional investors like BlackRock increasing their holdings.
Insider transactions included substantial buying activity by Asit Parikh in May 2026.

Get $PHAT trade alerts by text

We text you when insiders, Congress or big funds trade $PHAT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Phathom Pharmaceuticals, Inc. alert may contain errors. Disclosures

On June 17, 2026, HC Wainwright reiterated its buy rating for PHAT, setting a price target of $26. This reaffirmation by analyst Matthew Caufield underscores confidence in PHAT's potential upside, as the stock traded at $10.43 on the market.

Other Institutional Activity in PHAT

Several institutional investors have shown interest in PHAT. BlackRock, Inc. increased its holdings by 506,448 shares, bringing its total to 4,061,996 shares valued at approximately $45.1 million. Invesco Ltd. also added 401,614 shares, resulting in a total of 4,322,060 shares worth about $48 million. Millennium Management LLC made a significant increase, adding 1,940,729 shares to reach a total of 4,022,909 shares valued at about $44.7 million.

Phathom Pharmaceuticals, Inc. Stock Up 39.4%

Shares of PHAT traded at $10.43. The stock has seen various levels of institutional interest, as reflected in recent trading activity and analyst ratings.

12-month forecast

$PHAT price target

Phathom Pharmaceuticals, Inc. daily closes and this analyst's $26 target. Not advice.

Insider Buying and Selling at Phathom Pharmaceuticals, Inc.

Recent insider activity at PHAT includes multiple transactions by Asit Parikh. On May 22, 2026, Parikh bought and sold 28,000 shares. Earlier, on May 20, 2026, Parikh purchased 17,500 shares at an average price of $4.95. Additionally, on May 19, 2026, both Parikh and James Topper acquired 24,122 shares each.

Analysts Set New Price Targets

On June 17, 2026, HC Wainwright & Co. reiterated its buy rating with a $26 price target. Earlier, on March 27, 2026, Barclays upgraded its rating to buy with an $18 target. Guggenheim maintained a buy rating with a $25 target on February 27, 2026. The consensus among analysts is generally positive, with a majority recommending a buy.

Bottom Line

HC Wainwright's reaffirmation of its buy rating for PHAT with a $26 target highlights ongoing confidence in the company's future prospects. Institutional investors like BlackRock and Millennium Management have increased their positions, indicating a broader interest in the stock. Insider buying activity further adds to the narrative of potential growth, although investors should remember that these insights are based on past filings and may not represent current positions.